Nielsen IAG: Drug Spots Lose Potency

Leaders from Glossier, Shopify, Mastercard and more will take the stage at Brandweek to share what strategies set them apart and how they incorporate the most valued emerging trends. Register to join us this September 23–26 in Phoenix, Arizona.

NEW YORK If you think that marketing in the drug category is becoming less interesting and more monotonous, you’re right.

A ranking of the most-recalled prescription drug ads shows that such efforts became less memorable for consumers between this year and last, as measured by Nielsen IAG, New York. (Adweek is a unit of the Nielsen Co.)

The ads consumers remembered best in 2007 were executions for Schering-Plough’s allergy drug Nasonex, Takeda’s sleeping pill Rozerem, Schering’s anti-cholesterol brand Vytorin, Pfizer’s anti-cholesterol brand Lipitor and its anti-smoking brand Chantix, and Sepracor’s insomnia med Lunesta.

But midway through 2008, all of those brands have run into controversy or economic difficulties — and several have pulled some or all of their consumer advertising.

What’s

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in